Purdue Pharmaceuticals, L.P.
One Stamford Forum
About Purdue Pharmaceuticals, L.P.
Purdue Pharmaceuticals, L.P., headquartered in Stamford, CT, is a privately held pharmaceutical company founded by physicians and focused on meeting the needs of healthcare providers and the patients in their care. Together with its independent associated companies, Purdue is dedicated to finding, developing, and bringing to market new medicines and related products that improve health outcomes. The company has long been known for its pioneering research on persistent pain, a principal cause of human suffering.
Purdue also has a growing line of non-prescription products including laxatives, microbicides, and nutraceuticals. The company is dedicated to serving the evolving needs of healthcare providers, patients, and caregivers with prescription and non-prescription medicines. A commitment to innovation and caring spans every aspect of the organization, from discovering and launching new medicines to demonstrating their medical value.
Purdue has led the battle against inadequate treatment of pain by developing sustained-release medications to manage pain. Its sales, marketing, and medical education professionals provide the healthcare community with comprehensive educational materials and programs relating to pain management.
In 1993, Purdue established Partners Against Pain® as a resource to help patients, caregivers, and healthcare professionals advance standards of pain care and alleviate unnecessary suffering through education and advocacy. Purdue has also assumed a leading role in addressing the serious public health problem of prescription drug abuse, supporting programs intended to help stem abuse.
At its research facilities in Cranbury, New Jersey, Purdue scientists are discovering new compounds to treat pain and developing formulations and delivery systems to help improve patient safety.
209 articles with Purdue Pharmaceuticals, L.P.
Company Names Steve Miller Chairman of the Board of Directors and Marc Kesselman Senior Vice President and General Counsel
Eisai and Purdue Pharma Announce Oral Presentation of Latest Clinical and Non-Clinical Data on Lemborexant at 43rd Annual Meeting of the Japanese Society of Sleep Research
Presentation includes data from first-ever Phase 3 head-to-head superiority comparison vs zolpidem ER in patients with a sleep-wake disorder
With increased worries over the addictive nature of opioid-based pain treatments, more and more companies are focusing on the development of effective treatments without the addictive nature.
Purdue Pharma, best known for selling painkiller OxyContin, announced it laid off approximately 350 staffers.
Purdue Pharmaceuticals is facing a new legal challenge over its OxyContin marketing practices.
Studies measured postural stability after middle-of-the-night awakening and next morning compared to zolpidem ER, as well as next-morning driving performance
Purdue Pharmaceuticals has named a new head of corporate social responsibility as it continues to grapple with negative attention due to the rampant opioid crisis across the United States.
Sitting before a Congressional panel Tuesday the heads of pharmaceutical distributing companies said their mea culpas over not doing more to limit the flow of prescription opioids to certain parts of the country.
Scandals are nothing new in any industry. The pharmaceutical and biotech industry are certainly no strangers to scandals – just ask convicted scandal-magnet Martin Shkreli.
Utah’s Salt Lake County is the latest governing body to enter the legal battle against opioid manufacturers, distributors and prescribers. Governments are seeking financial restitution for the funds they have spent on battling addiction to prescription opioid medications.
Purdue Pharma L.P. Names Dr. John Renger as Vice President, Head of Research & Development and Regulatory Affairs
Purdue Pharma L.P. announced that John Renger, Ph.D., has been appointed Vice President, Head of Research & Development and Regulatory Affairs.
As legal battles over opioid drugs slowly move through the courts the U.S. Department of Justice is adding its weight to the matter. This week the DOJ asked the courts for permission to help settle disputes brought by state and local governments against opioid manufacturers and distributors.
Company Profile for Purdue Pharma L.P.
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant Including First-Ever Phase 3 Head-to-Head Superiority Comparison Versus Zolpidem ER in Patients With Sleep Disorder
The Phase 3 pivotal study, SUNRISE 1, achieved its primary and key secondary objectives versus placebo and versus an active comparator.
Fifty-Two Week Safety Study on Symproic® (naldemedine) for Opioid-induced Constipation (OIC) in Adults with Chronic Non-cancer Pain Published in PAIN
The study is the first to investigate a peripherally-acting mu-opioid receptor antagonist (PAMORA) over the course of 52 weeks in a randomized, placebo-controlled and double-blind manner.
With no end to the national opioid crisis in sight, the U.S. Department of Justice announced a plan to form a task force that will target opioid manufacturers and distributors.
Purdue Pharma L.P. today announced that Marcelo Bigal, MD, PhD has been appointed Chief Medical Officer (CMO).
That announcement is a big change in the way Purdue has aggressively marketed OxyContin in the past.
Purdue Pharma, L.P. today announced the funding of three grants for investigator-initiated research on developing clinically relevant and useful tools to assist in the assessment of chronic pain, including research on Virtual Reality (VR) technology to assess chronic pain intensity; electroencephalograph (EEG) alpha activity as an objective measurement of pain; and the relationship between pain and attentional processes and cognitive functioning.
Eisai and Purdue Pharma L.P. Presented Lemborexant Data From Research Studies at ACNP Annual Meeting
The Asakura et al. poster presentation reported a non-clinical study demonstrating differences in lemborexant abuse liability when compared to a currently marketed insomnia treatment, suvorexant.